Igor Espinoza-Delgado
Overview
Explore the profile of Igor Espinoza-Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subramanian S, Bates S, Wright J, Espinoza-Delgado I, Piekarz R
Pharmaceuticals (Basel)
. 2016 Oct;
3(9):2751-2767.
PMID: 27713375
The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this...
2.
Norsworthy K, Cho E, Arora J, Kowalski J, Tsai H, Warlick E, et al.
Leuk Res
. 2016 Sep;
49:90-7.
PMID: 27619199
Pre-clinical data in non-M3 AML supports the use of differentiation therapy, but clinical activity has been limited. Myeloid growth factors can enhance anti-leukemic activity of differentiating agents in vitro. We...
3.
How J, Minden M, Brian L, Chen E, Brandwein J, Schuh A, et al.
Leuk Lymphoma
. 2015 Feb;
56(10):2793-802.
PMID: 25682963
This phase I trial evaluated two schedules of escalating vorinostat in combination with decitabine every 28 days: (i) sequential or (ii) concurrent. There were three dose-limiting toxicities: grade 3 fatigue...
4.
Deming D, Ninan J, Bailey H, Kolesar J, Eickhoff J, Reid J, et al.
Invest New Drugs
. 2013 Oct;
32(2):323-9.
PMID: 24114123
Background: Accumulating evidence shows evidence of efficacy with the combination of vorinostat and bortezomib in solid tumors. We previously examined a once-daily continuous dosing schedule of vorinostat in combination with...
5.
Schelman W, Traynor A, Holen K, Kolesar J, Attia S, Hoang T, et al.
Invest New Drugs
. 2013 Oct;
31(6):1539-46.
PMID: 24114121
Background: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid...
6.
Kolesar J, Traynor A, Holen K, Hoang T, Seo S, Kim K, et al.
Cancer Chemother Pharmacol
. 2013 Aug;
72(3):661-7.
PMID: 23903894
Introduction: Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to...
7.
Stearns V, Jacobs L, Fackler M, Tsangaris T, Rudek M, Higgins M, et al.
Clin Cancer Res
. 2013 May;
19(14):4008-16.
PMID: 23719261
Purpose: Agents that target the epigenome show activity in breast cancer models. In preclinical studies, the histone deacetylase inhibitor vorinostat induces cell-cycle arrest, apoptosis, and differentiation. We evaluated biomarker modulation...
8.
Gojo I, Tan M, Fang H, Sadowska M, Lapidus R, Baer M, et al.
Clin Cancer Res
. 2013 Feb;
19(7):1838-51.
PMID: 23403629
Purpose: To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or...
9.
Lee E, Puduvalli V, Reid J, Kuhn J, Lamborn K, Cloughesy T, et al.
Clin Cancer Res
. 2012 Aug;
18(21):6032-9.
PMID: 22923449
Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma...
10.
Muscal J, Thompson P, Horton T, Ingle A, Ahern C, McGovern R, et al.
Pediatr Blood Cancer
. 2012 Aug;
60(3):390-5.
PMID: 22887890
Background: A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. Procedure: Oral...